Figure 1.
Response to once-daily ponatinib. Twelve months (A) and median dose intensity and response over time (B). (A) ≤1 % BCR-ABL1IS at 12 months (98.3% CI). (B) Median dose intensity and ≤1% BCR-ABL1IS by 6, 12, and 24 months.
Response to once-daily ponatinib. Twelve months (A) and median dose intensity and response over time (B). (A) ≤1 % BCR-ABL1IS at 12 months (98.3% CI). (B) Median dose intensity and ≤1% BCR-ABL1IS by 6, 12, and 24 months.